Drugs / nivasorexant
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05254548 | Feb → Apr 2022 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04753164 | Feb 2021 → Mar 2022 | binge eating disorder | Idorsia Pharmaceuticals Ltd. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-05-10 | Idorsia Pharmaceuticals Ltd. | Results Phase 2a study results in binge eating disorder idorsia.com ↗
ACT-539313, a selective orexin-1 receptor antagonist, did not show an improvement over placebo in reducing the number of binge eating days per week in adult patients with moderate to severe binge eating disorder – the primary endpoint was therefore not met. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-05-10 | Idorsia Pharmaceuticals Ltd. | Phase 2a study results in binge eating disorder idorsia.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nivasorexant | “Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in...” PMID 37800597 ↗ Oct 2023 |
| Known as | ACT-539313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04753164 ↗ |
| Modality | Small molecule | — CHEMBL3892369 ↗ |
| Route | Oral | “taken orally” NCT04753164 ↗ |